Abstract
The use of biologic agents has revolutionized the management of rheumatoid arthritis (RA) in the past two decades. These biologic agents directly target molecules and cells involved in the pathogenesis of RA. Biologic agents indeed lead to a better prognosis and clinical remission in patients with RA, especially in patients who are not well-controlled with traditional disease-modifying anti-rheumatic drugs (DMARDs). Currently, five TNF inhibitors (infliximab, etanercept, adalimumab, golimumab and certolizumab pegol), an IL-6 receptor antagonist (tocilizumab), an IL-1 receptor antagonist (anakinra), a B cell depleting agent (rituximab) and a T cell co-stimulation inhibitor (abatacept) have been approved for the treatment of RA. With the increased understanding of the pathogenic mechanisms of RA and advantages in manufacturing biotechnology of pharmaceutical companies, a series of novel biologic therapeutic approaches are being developed. In the present paper, we will summarize the biologic agents currently available to treat RA, and the prospective biologic therapies that might be used in the management of RA in future.
Keywords: Biologic therapy, cell-targeted therapy, cytokine-targeted therapy, rheumatoid arthritis.
Current Pharmaceutical Biotechnology
Title:The Use of Biologic Therapies in the Treatment of Rheumatoid Arthritis
Volume: 15 Issue: 6
Author(s): Dashan Wang, Yan Li, Yuan Liu and Guixiu Shi
Affiliation:
Keywords: Biologic therapy, cell-targeted therapy, cytokine-targeted therapy, rheumatoid arthritis.
Abstract: The use of biologic agents has revolutionized the management of rheumatoid arthritis (RA) in the past two decades. These biologic agents directly target molecules and cells involved in the pathogenesis of RA. Biologic agents indeed lead to a better prognosis and clinical remission in patients with RA, especially in patients who are not well-controlled with traditional disease-modifying anti-rheumatic drugs (DMARDs). Currently, five TNF inhibitors (infliximab, etanercept, adalimumab, golimumab and certolizumab pegol), an IL-6 receptor antagonist (tocilizumab), an IL-1 receptor antagonist (anakinra), a B cell depleting agent (rituximab) and a T cell co-stimulation inhibitor (abatacept) have been approved for the treatment of RA. With the increased understanding of the pathogenic mechanisms of RA and advantages in manufacturing biotechnology of pharmaceutical companies, a series of novel biologic therapeutic approaches are being developed. In the present paper, we will summarize the biologic agents currently available to treat RA, and the prospective biologic therapies that might be used in the management of RA in future.
Export Options
About this article
Cite this article as:
Wang Dashan, Li Yan, Liu Yuan and Shi Guixiu, The Use of Biologic Therapies in the Treatment of Rheumatoid Arthritis, Current Pharmaceutical Biotechnology 2014; 15 (6) . https://dx.doi.org/10.2174/138920101506140910150612
DOI https://dx.doi.org/10.2174/138920101506140910150612 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Biologic Characteristics of Bone Marrow Mesenchymal Stem Cells in Myelodysplastic Syndromes
Current Stem Cell Research & Therapy Cardiovascular Disease: What's All the AGE/RAGE About?
Cardiovascular & Hematological Disorders-Drug Targets Comparative Molecular Characterization to Reveal Surface Behaviour of Non-proteolytic Bromelain Mutants
Current Pharmaceutical Biotechnology Visfatin and Rheumatoid Arthritis: Pathogenetic Implications and Clinical Utility
Current Rheumatology Reviews Genetic Variations in Telomere Maintenance, with Implications on Tissue Renewal Capacity and Chronic Disease Pathologies
Current Pharmacogenomics and Personalized Medicine Extracellular Vesicles as Drug Delivery Vehicles for Rheumatoid Arthritis
Current Stem Cell Research & Therapy Recent Patents Concerning Modulators of Protein Kinase C
Recent Patents on DNA & Gene Sequences Macrophage Activation Syndrome in Childhood Rheumatic Diseases
Current Rheumatology Reviews Paracetamol (Acetaminophen) Efficacy and Safety in the Newborn
Current Drug Metabolism Generation of Pharmacophore and Atom Based 3D-QSAR Model of Novel Isoquinolin-1-one and Quinazolin-4-one-type Inhibitors of TNFα
Medicinal Chemistry Pharmacological Applications of Antioxidants: Lights and Shadows
Current Drug Targets IL-1 as a target in inflammation
Endocrine, Metabolic & Immune Disorders - Drug Targets Comparison of Large Proteomic Datasets
Current Proteomics Antioxidant Effects of Chalcones during the Inflammatory Response: An Overall Review
Current Medicinal Chemistry Monoclonal Antibodies: A Target Therapy for Multiple Sclerosis
Inflammation & Allergy - Drug Targets (Discontinued) The Seek of Neuroprotection: Introducing Cannabinoids
Recent Patents on CNS Drug Discovery (Discontinued) Modifiers of Hearing Impairment in Humans and Mice
Current Genomics Supramolecular Chiro-Biomedical Assays and Enantioselective HPLC Analyses for Evaluation of Profens as Non-Steroidal Anti-Inflammatory Drugs, Potential Anticancer Agents and Common Xenobiotics
Current Drug Discovery Technologies Analysis of Comparative Proteomic and Potent Targets of Peniciketal A in Human Acute Monocytic Leukemia
Anti-Cancer Agents in Medicinal Chemistry The Therapeutic Potential of Adenosine Triphosphate as an Immune Modulator in the Treatment of HIV/AIDS: A Combination Approach with HAART
Current HIV Research